COVID19 The Great Decentralized Clinical Trials Accelerator

October 21, 2020

With greater convenience for patients and reduced geographic, financial, and practical barriers to participation, the pandemic has pushed the industry toward swift adoption of Decentralized Clinical Trials (DCTs). The global health crisis has been a learning experience for patients and sites in ways that nobody could have anticipated. Still, with new forms of communication thrust upon them, people have adopted and thrived. With all that has been learned, it is likely that DCTs will be here to stay long after this terrible virus has been tamed.

Learn more from Roz Round, Parexel’s Vice President, Patient Innovation Center about her firsthand experience with COVID19 and how it reinforced her commitment to DCTs as a way of ensuring patient safety and enabling ongoing trial participation.

Previous Article
Getting the small steps right for our biotech customers to make an exponential difference in patients’ lives
Getting the small steps right for our biotech customers to make an exponential difference in patients’ lives

Biotech companies are the driving force behind the industry’s R&D pipeline as they develop and launch incre...

Next Flipbook
Rare disease clinical trial patient identification and recruitment
Rare disease clinical trial patient identification and recruitment

×

Lets start a conversation...

First Name
Last Name
Job Title
Company Name
Country
Therapeutic Area Interest - optional
Tell us how we can help
Thank you! We'll be in touch soon.
Error - something went wrong!